Therapy News and Research

RSS

Low dose carbon monoxide therapy can prevent fetal death

Heme oxygenase-1 is essential for the growth of blood vessels in the placenta and in establishing blood flow in the umbilical cord. Too little HO-1 can lead to a restriction in the growth of the fetus and even in fetal death and miscarriage. New research published in BioMed Central's open access journal Medical Gas Research has shown that low dose carbon monoxide therapy is able to restore placental function and prevent fetal death in mice, without any detrimental effects.

19 Feb 2012

Botox efficacy uncertain in treating migraine says NICE

Botox – used as an anti-wrinkle agent - is unlikely to be recommended for the treatment of chronic migraines on the NHS in England and Wales. According to the National Institute for Health and Clinical Excellence (NICE) draft guidelines there is insufficient evidence that it works.

18 Feb 2012

OICR launches Phase III Active Surveillance Magnetic Resonance Imaging Study Trial

Dr. Nicole Onetto, Deputy Director and Chief Scientific Officer of the Ontario Institute for Cancer Research (OICR), today announced the launch of an innovative Phase III clinical trial that aims to determine whether multi-parametric magnetic resonance imaging (MRI) coupled with transrectal ultrasound (TRUS) guided biopsy (called fusion technology) can accurately identify men with prostate cancer who are at risk of developing aggressive disease.

18 Feb 2012

Medicare cuts include psychotherapy payment reduction

Medicare recipients currently receiving mental health outpatient services stand to be affected by the payroll tax legislation passed by Congress today. As a result of the new law, which President Obama is expected to sign, payment for Medicare outpatient psychotherapy services will be cut by five-percent beginning March 1.

18 Feb 2012

FDA prioritizes review of Ra-223 and MDV3100 for treating CRPC

The arsenal of prostate cancer treatments for men with advanced prostate cancer may soon be strengthened as the FDA prioritizes the review of both Ra-223 and MDV3100 for treating metastatic castration-resistant prostate cancer (CRPC). Based on positive, independent research of each drug, better survival rates and improved bone health for patients with late-stage prostate cancer may be within reach.

18 Feb 2012

Elekta's Fraxion integrates all proven cranial immobilization options in a single solution

The Fraxion head frame helps ensure accuracy and precision in stereotactic radiation therapy (SRT) of cancer targets in the brain and cranium. Elekta's Fraxion is the first to introduce an innovative system that integrates all proven cranial immobilization options in a single solution.

From Elekta 18 Feb 2012

Substituting antiepileptic drugs may lead to increase in risk of epilepsy

The substitution of brand-name antiepileptic drugs with cheaper generic equivalents has been an ongoing point of contention among doctors, federal officials and people with epilepsy.

18 Feb 2012

UM's Momentum2 Campaign receives $100M gift from DRIF

Accelerating its longstanding commitment to cure diabetes, the Diabetes Research Institute Foundation is making the lead gift of $100 million to Momentum2: The Breakthrough Campaign for the University of Miami.

18 Feb 2012

PCMA launches That's What PBMs Do campaign in Maryland

The Pharmaceutical Care Management Association (PCMA) has launched a new ad campaign in Maryland that highlights the core value proposition of pharmacy benefit managers.

18 Feb 2012

EMA CHMP recommends CTI's Pixuvri for conditional approval

Cell Therapeutics, Inc. announced today that Pixuvri has been granted a positive opinion for conditional approval from the European Medicines Agency's Committee for Medicinal Products for Human Use.

18 Feb 2012

Study: Thrombolytic therapy can be safely used in children with stroke

New research looks at whether clot-busting drugs can safely be given to children who have strokes. The research was released today and will be presented at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21 to April 28, 2012.

18 Feb 2012

Nano-enabled intranasal formulation of teriparatide can treat osteoporosis

The University of Nottingham spin-out company, Critical Pharmaceuticals, has announced a -545,000 collaboration with the University to develop a nano-enabled intranasal formulation of teriparatide for the treatment of osteoporosis.

18 Feb 2012

Corcept receives FDA approval for Korlym to treat endogenous Cushing's syndrome

Today, Korlym (mifepristone) was approved by the U.S. Food and Drug Administration to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing's syndrome.

18 Feb 2012

FDA approves Medtronic's Resolute Integrity DES to treat CAD

Advancing the clinical practice of interventional cardiovascular medicine, Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Resolute Integrity Drug-Eluting Stent (DES) for the treatment of coronary artery disease.

From Medtronic 17 Feb 2012

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.

17 Feb 2012

Digital games become an important tool for self-management of illness and chronic conditions

Millions of dollars and immeasurable hours of research and development are being invested to develop and employ increasingly sophisticated hardware and software technologies to deliver innovative new personalized health care interventions.

17 Feb 2012

Four new drugs can extend survival and prognosis of prostate cancer

After a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer a chronic illness instead of a terminal disease, a leading Colorado prostate cancer expert says.

17 Feb 2012

Nordion celebrates first anniversary of market launch of TheraSphere

Nordion Inc., a leading provider of products and services to the global health science market, today celebrated the first anniversary of the market introduction of TheraSphere, an innovative radioembolic liver cancer therapy, in the Republic of Turkey.

17 Feb 2012

Unique board game to help bridge gaps between various health disciplines

A unique board game developed by a group of medical students at Western University will help bridge gaps between various health disciplines to better educate students about their roles in interdisciplinary health teams.

17 Feb 2012

First accurate predictive model to differentiate between dengue fever and dengue hemorrhagic fever

Researchers at the University of Texas Medical Branch have developed the first accurate predictive model to differentiate between dengue fever (DF) and its more severe form, dengue hemorrhagic fever (DHF).

17 Feb 2012